I think it's critical that we have national data. You have the opportunity through national data to understand the problem in the whole of the country, to compare our situation with that of other countries and other jurisdictions.
There are challenges. On the harm side, you have death data. Detecting that a death is the result of opioid poisoning is challenging. We're working on some guidelines for coroners, with their participation, to help standardize this. You can have dramatically different results on a death certificate with respect to the cause of death, depending on who the coroner is. We really don't have comparable data nationally, and we need to work on that.
On the drug claims side, which is one part of the supply equation, we're working towards nationally comparable data for all drug claims. We don't have nationally comparable data in private prescription claims. We only have that for three provinces at the moment, but through some of the new electronic records, drug information systems, we ought to have more complete data soon.
These are priority areas that we're working on now, and part of the investment from Health Canada is directed toward those aims.